Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 (Vaxneuvance) in Children with Sickle Cell Disease
NCT03731182Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2019
- Primary completion
- Jun 2020
- Modality
- Split/Subunit Vaccines
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection (2 arms), sponsored by Merck & Co. Primary endpoints: Percentage of Participants With a Solicited Injection-site Adverse Event at 14 days, Percentage of Participants With a Solicited Systemic Adverse Event at 14 days and 2 more. Started Jan 2019; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03731182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03731182.